Prospective determination of plasma imipenem concentrations in critically ill children

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 7, 2006, Pages 2563-2568

  Giannoni, Eric ^a   Moreillon, Philippe ^b   Cotting, Jacques ^a   Moessinger, Adrien ^a   Bille, Jacques ^a   Décosterd, Laurent ^a   Zanetti, Giorgio ^a   Majcherczyk, Paul ^b   Bugnon, Denis ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c University School of Medicine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; CREATININE; IMIPENEM;

ABSENCE OF SIDE EFFECTS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; ENTEROBACTER CLOACAE; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; NEUROLOGIC DISEASE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SKIN DISEASE; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CILASTATIN; CRITICAL ILLNESS; CROSS INFECTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPENEM; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE;

EID: 33745601994     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01149-05     Document Type: Article

References (25)

1. Begue, P. C., S. Baron, P. Challier, J. L. Fontaine, and G. Lasfargues. 1987. Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates. Scand. J. Infect. Dis. 52(Suppl.):40-45.
2. Belzberg, H., J. Zhu, E. E. Cornwell III, J. A. Murray, J. Sava, A. Salim, G. C. Velmahos, and M. A. Gill. 2004. Imipenem levels are not predictable in the critically ill patient. J. Trauma 56:111-117.
3. Besunder, J. B., M. D. Reed, and J. L. Blumer. 1988. Principles of drug biodisposition in the neonate. I. A critical evaluation of the pharmacokinctic-pharmacodynamic interface. Clin. Pharmacokinet. 14:189-216.
4. Blumer, J. L. 1996. Pharmacokinetic determinants of carbapenem therapy in neonates and children. Pediatr. Infect. Dis. J. 15:733-737.
5. Bugnon, D., E. Giannoni, P. Majcherczyk, M. P. Glauser, and P. Moreillon. 2002. Pitfalls in cefepime titration from human plasma: plasma- and temperature-related drug degradation in vitro. Antimicrob. Agents Chemother. 46:3654-3656.
6. Claesson, G., M. Eriksson, and J. D. Rogers. 1992. Pharmacokinetics of imipenem/cilastatin sodium in children with peritonitis. Pharmacol. Toxicol. 71:103-106.
7. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
8. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36:S42-S50.
9. Engelhard, D., I. Shalit, H. R. Stutman, R. Greenwood, J. Griffis, and M. I. Marks. 1986. Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients. Pediatr. Pharmacol. (New York) 5:273-279.
10. Garcia-Capdevila, L., C. Lopez-Calull, C. Arroyo, M. A. Moral, M. A. Mangues, and J. Bonal. 1997. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J. Chromatogr. B 692:127-132.
11. Gibaldi, M., and D. Perrier. 1982. Noncompartmental analysis based on statistical moment theory. Marcel Dekker, New York, N.Y.
12. Gunderson, B. W., G. H. Ross, K. H. Ibrahim, and J. C. Rotschafer. 2001. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21:302S-318S.
13. Henry, N. K., J. L. Hoecker, and K. H. Rhodes. 2000. Antimicrobial therapy for infants and children: guidelines for the inpatient and outpatient practice of pediatric infectious diseases. Mayo Clin. Proc. 75:86-97.
14. Jacobs, R. F., G. L. Kearns, J. M. Trang, A. L. Brown, B. Marmer, J. C. McIntosh, F. L. Underwood, and R. B. Kluza. 1984. Single-dose pharmacokinetics of imipenem in children. J. Pediatr. 105:996-1001.
15. Livermore, D. M. 1995. Bacterial resistance to carbapenems. Adv. Exp. Med. Biol. 390:25-47.
16. Majcherczyk, P. A., P. Moreillon, L. A. Decosterd, D. Sanglard, J. Bille, M. P. Glauser, and O. Marchetti. 2002. Single-step extraction of fluconazole from plasma by ultra-filtration for the measurement of its free concentration by high performance liquid chromatography. J. Pharm. Biomed. Anal. 28:645-651.
17. Mohr, J. F., A. Wanger, and J. H. Rex. 2004. Pharmacokinetic/ pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn. Microbiol. Infect. Dis. 48:125-130.
18. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
19. Pollack, M. M., K. M. Patel, and U. E. Ruttimann. 1996. PRISM III: an updated pediatric risk of mortality score. Crit. Care Med. 24:743-752.
20. Prader, A., R. H. Largo, L. Molinari, and C. Issler. 1989. Physical growth of Swiss children from birth to 20 years of age. First Zurich longitudinal study of growth and development. Helv. Paediatr. Acta 52(Suppl.):1-125.
21. Reed, M. D., R. M. Kliegman, T. S. Yamashita, C. M. Myers, and J. L. Blumer. 1990. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob. Agents Chemother. 34:1172-1177.
22. Routledge, P. A. 1994. Pharmacokinetics in children. J. Antimicrob. Chemother. 34(Suppl. A):19-24.
23. Steward, C. D., J. M. Mohammed, J. M. Swenson, S. A. Stocker, P. P. Williams, R. P. Gaynes, J. E. McGowan, Jr., and F. C. Tenover. 2003. Antimicrobial susceptibility testing of carbapenems: multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates. J. Clin. Microbiol. 41:351-358.
24. Tegeder, I., A. Schmidtko, L. Brautigam, A. Kirschbaum, G. Geisslinger, and J. Lotsch. 2002. Tissue distribution of imipenem in critically ill patients. Clin. Pharmacol. Ther. 71:325-333.
25. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.